Telomir Pharmaceuticals (TELO) Income Statement (2023 - 2025)
Income Statement report data from Mar 31, 2023 to Dec 31, 2025 for Telomir Pharmaceuticals (TELO).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | ||||||||||||
Research And Development | 1.30M (+71.05%) | 760K (+1800.00%) | 40K (-88.24%) | 340K (+61.90%) | 210K (-66.67%) | 630K (+6.78%) | 590K (-26.25%) | 800K | - | 260K (-61.19%) | 670K (+52.27%) | 440K |
Selling General And Administrative | 840K (+115.38%) | 390K (-92.25%) | 5.03M (+171.89%) | 1.85M (-29.92%) | 2.64M (-50.93%) | 5.38M (+511.36%) | 880K (+18.92%) | 740K | - | 100K (+66.67%) | 60K (+50.00%) | 40K |
Operating Expenses | 2.13M (+85.22%) | 1.15M (-77.32%) | 5.07M (+131.51%) | 2.19M (-23.16%) | 2.85M (-52.58%) | 6.01M (+308.84%) | 1.47M (-23.44%) | 1.92M | - | 950K (-33.57%) | 1.43M (+197.92%) | 480K |
Operating Income | ||||||||||||
Operating Income | -2.19M | - | - | 2.19M | -1.92M | - | - | 1.92M | - | - | - | - |
Ebit | -6.43M (+484.55%) | -1.10M (-78.30%) | -5.07M | 2.19M | -11.07M (+84.81%) | -5.99M (+330.94%) | -1.39M | 1.92M | -9.33M (+445.61%) | -1.71M (+10.32%) | -1.55M (+222.92%) | -480.00K |
EBITDA | -2.06M (+87.27%) | -1.10M (-78.30%) | -5.07M (+132.57%) | -2.18M (-24.83%) | -2.90M (-51.59%) | -5.99M (+330.94%) | -1.39M (-27.60%) | -1.92M (-79.42%) | -9.33M (+882.11%) | -950.00K (-33.57%) | -1.43M (+197.92%) | -480.00K |
Other Income / Expenses | ||||||||||||
Interest Income | 80K (+100.00%) | 40K | - | - | 10K (-50.00%) | 20K (-33.33%) | 30K | - | - | - | - | - |
Interest Expense | - | - | - | - | - | - | - | 4.34M | - | 760K (+533.33%) | 120K | - |
Net Interest Income | 80K (+100.00%) | 40K | - | - | 4.35M (+21650.00%) | 20K (-33.33%) | 30K | -4.34M | - | - | - | - |
Other Non Operating Income | - | - | - | - | - | 20K | - | - | - | -760.00K | - | - |
Net Income | ||||||||||||
Net Income From Continuing Operations | -2.06M (+87.27%) | -1.10M (-78.30%) | -5.07M (+132.57%) | -2.18M (-24.83%) | -2.90M (-51.59%) | -5.99M (+330.94%) | -1.39M (-77.76%) | -6.25M (-33.01%) | -9.33M (+445.61%) | -1.71M (+10.32%) | -1.55M (+222.92%) | -480.00K |
Net Income | -2.06M (+87.27%) | -1.10M (-78.30%) | -5.07M (+132.57%) | -2.18M (-24.83%) | -2.90M (-51.59%) | -5.99M (+330.94%) | -1.39M (-77.76%) | -6.25M (-33.01%) | -9.33M (+445.61%) | -1.71M (+10.32%) | -1.55M (+222.92%) | -480.00K |